kentucky glp-1 intestinal paralysis class action Ozempic Lawsuits: FDA Warnings, Legal Actions, and What Patients Need to Know Unveiling The GLP-1 Adverse Gastric

In 2024 semaglutide (Wegovy) became the first weight loss drug to also be approved for the reduction of risk of serious cardiovascular events in patients with cardiovascular (CV) disease and obesity and overweight

Contract Research Organizations (CROs): CROs provide outsourced services to pharmaceutical companies, such as clinical trial management, data analysis, and regulatory support

Secondary outcomes included changes in MDS-UPDRS when on dopamine-based medication, as well as off-and-on state analysis of timed sit-stand-walk tests and scores from a battery of neuropsychological exams

Budney, A

Aging (Albany NY) 15(16):8044 Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N et al (2024) Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation

Naruse M, Naruse K, Yoshimoto T, et al